What the FDA labels say about taking them together
Everolimus and rifabutin
Everolimus's FDA label (Zortress) of February 12, 2026 names rifabutin in its drug interactions section; the rifabutin label PlainMeds reads does not name everolimus. The everolimus label: “Concurrent treatment with strong inhibitors and inducers of CYP3A4 is not recommended.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the rifabutin FDA label on DailyMed (effective September 1, 2026, REMEDYREPACK INC.).
What does the everolimus label say about rifabutin?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsConcurrent treatment with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) and inducers (e.g., rifampin, rifabutin) of CYP3A4 is not recommended.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsInhibitors and Inducers of CYP3A4 Coadministration of Zortress with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) or strong CYP3A4 inducers (e.g., rifampin, rifabutin) is not recommended without close monitoring of everolimus whole blood trough concentrations [see Drug Interactions (7)].
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the rifabutin label say about everolimus?
Rifabutin's label (effective September 1, 2026) does not name everolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Rifabutin), NDA050689 (Pfizer), as published by REMEDYREPACK INC., effective September 1, 2026 (SPL set 25a60937-cbbe-4a50-994f-2ce15203f589), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Rifabutin | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $8.14 per capsule 150 mg capsule |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once